Cancer screening company Nucleix raises 2.5 milion euros

Founded in 2008, Nucleix develops urine and blood-based non-invasive, molecular cancer screening tests. Israel-based Nucleix Ltd. has received 2.5 million euros in funding from Horizon 2020, the European Union’s research and innovation program, to develop its blood-based lung cancer early detection test, the company announced Monday. Nucleix received a grant of an undisclosed amount from the program in 2016.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !